Targeted Cancer Therapy for Patients With 17p Deletion
Time: 3:30 pm
day: Conference Day Two pt 2
Details:
• Breaking down clinical profile and new phase II escalation data of HDP-101 targeting BCMA in myeloma patients
• Laying out retrospective analysis and investigation in deletion models of 17p deletion as a biomarker and patient selection tool for amanitin payload ADCs
• Discussing future directions for clinical development and potential for patient selection investigation for precision medicine ADC development
